News
Displaying 211–220 of 508
-
ARVO 2021 Highlight: Update on Clinical Trial of jCyte’s Cellular Therapy for RP
Research NewsCellular treatment provided significant improvements in visual acuity for subpopulation of patients with better vision
-
Foundation Fighting Blindness and Usher 1F Collaborative to Launch Natural History Study
Foundation NewsThe project will help identify outcome measures for future clinical trials of potential USH1F therapies.
-
Foundation Fighting Blindness Appoints Claire M. Gelfman, Ph.D. as Chief Scientific Officer
Foundation NewsDr. Gelfman brings over twenty years of successful ophthalmic research and development experience to the Foundation executive team.
-
SparingVision to Acquire Therapy for Resurrecting Dormant Cones for Vision Restoration
Research NewsThe gene-agnostic approach shows promise for people with late-stage RP and related diseases.
-
Encouraging Early Report for Three Patients in LCA1-GUCY2D Gene Therapy Clinical Trial
Research NewsDevelopment of the emerging gene therapy is being funded by the Foundation’s RD Fund
-
Foundation Invests $5.5 Million in Seven New Translational Research Projects
Research NewsProjects target a variety of conditions including: age-related macular degeneration, Stargardt disease, retinitis pigmentosa, and Usher syndrome type 3A
-
Bionic Sight’s Optogenetic Therapy Enables Blind Patients to Detect Light and Motion in Early Trial
Research NewsThe approach holds potential for restoring vision to people with little or no vision
-
ProQR’s RNA Therapy for USH2A Performs Well in Phase 1/2 Clinical Trial
Research NewsThe company is planning two Phase 2/3 clinical trials for the treatment
-
Foundation Fighting Blindness Launches Chapter Program Rebrand
Foundation NewsThe program honors Lulie Gund and her legacy and commitment to the Foundation’s Chapter community.
-
Foundation’s No-Cost Program Increased Genetic Testing Rates for IRD Patients
Research NewsMore than 8,000 people have applied for genetic testing through the Foundation’s program
.png)
